Affimed Reports First Quarter 2024 Financial Results & Business Update
- Initial data from the LuminICE-203 study shows 85.7% overall response rate (ORR) (6 of 7 patients); 4 out of...
Pharmaceutical
Helsinn Group and Chugai Pharma Europe sign a partnership agreement renewal to commercialize AKYNZEO® in the UK and Ireland
Helsinn Group and Chugai Pharma Europe sign a partnership agreement renewal to commercialize AKYNZEO® in the UK and Ireland Lugano,...
Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan
Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and...
T-Therapeutics appoints Dr David Hung as Chairman
T-Therapeutics appoints Dr David Hung as Chairman Industry veteran, founder of Medivation and serial entrepreneur joins T-Therapeutics to support development...
Crossject appoints Dan Chiche, MD as Chief Medical Officer North America
Brings extensive experience in drug development in the U.S and internationally and in maximizing value of medical productsReinforces leadership team...
Junshi Biosciences Announces Phase 3 Study of Toripalimab Combined with Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma Meets Primary Endpoint
SHANGHAI, June 11, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading...
Opthea Announces Placement and Partially Underwritten Entitlement Offer to Raise up to Approximately A$227.3 million (US$150.0 million¹)
Financing extends Opthea’s cash runway through Phase 3 topline data readout for both pivotal trials of sozinibercept in wet AMD...
Scilex Holding Company Announces 5-Year Term of $100 Million Financing with Royalty-Based Payments and Potential Strategic Transactions with Perigrove and its Portfolio Companies
PALO ALTO, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative...
Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
14-month data show treatment with setrusumab resulted in a large, sustained 67% reduction in annualized fracture rate and persistent median annualized fracture...
Alzheon Raises $100 Million Series E Financing Round to Advance Development and Commercialization of Oral Tablet ALZ-801/Valiltramiprosate for Treatment of Alzheimer’s Disease
Proceeds Will Support Completion of Pivotal APOLLOE4 Phase 3 Study Evaluating ALZ-801/Valiltramiprosate and Regulatory Filings for Patients with Early Alzheimer’s...
Canary Speech Secures $13 Million in Series A Funding to Change How the World’s Top Healthcare Organizations Screen for Mental Wellness and Cognitive Health
Led by Cortes Capital, LLC, Sorenson Communications, LLC., SMK (Japan), and Hackensack Meridian Health, Series A funding expands the AI-driven...
Biophytis Announces the Successful Industrial Transfer of BIO101 (20-hydroxyecdysone) Production by its Service Provider Seqens
PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / June 12, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the...
MindBio Therapeutics Reports Secondary Data: Improvement of Psychological Outcomes & Safety Results in Depressed Patients from Phase 2A Depression Trial
VANCOUVER, BC / ACCESSWIRE / June 12, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), a leading biopharmaceutical...
Waters | Wyatt Technology Forms a Strategic Collaboration With Bioz to Promote Scientific Discovery by Leveraging Publications
PALO ALTO, CA / ACCESSWIRE / June 12, 2024 / Bioz, Inc., a cutting-edge AI software company that is deeply...
Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb
Key scientific achievement advances the joint pipeline in the strategic neuroscience partnership with Bristol Myers Squibb and earns a payment...
Between Us Clinic Survey Reveals Urologists’ Top Alternative ED Treatment Recommendations
Between Us Clinic Survey Reveals Urologists' Top ED Treatment Recommendations: Diet, Exercise, and Mindfulness Meditation Lead the Way. FORT LAUDERDALE,...
Expert.ai Wins Duck Creek 2024 Hatch-a-Thon
Expert.ai showcased its innovative AI-powered claims solution at Formation '24 conference in Dallas, where Duck Creek Advisory Board and attendees...
ACTO ACQUIRES 4TH DOWN SOLUTIONS, BRINGING TOGETHER TWO INDUSTRY LEADERS
Strategic Acquisition Adds to ACTO's Organic Customer Growth in Top 50 Pharma KISSIMMEE, Fla., June 11, 2024 /PRNewswire/ - Today...
Quest Diagnostics Completes Acquisition of Select PathAI Diagnostics’ Lab Assets from PathAI, Accelerating Adoption of AI and Digital Pathology to Speed Cancer Diagnosis
PathAI remains an independent company, focused on developing innovative AI and digital pathology solutions SECAUCUS, N.J. and BOSTON, June 11,...
AxoSim Appoints Alif Saleh as Chief Executive Officer to Drive Market Adoption
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer NEW ORLEANS, June 11, 2024 /PRNewswire/ -- AxoSim, a life...